Takashi Kaneshiro

Takashi Kaneshiro

Auto-generated profile, based on publicly available information

Takashi Kaneshiro

Department of Cardiovascular Medicine Fukushima Medical University Fukushima Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
TKTakashi Kaneshiro
Takashi Kaneshiro
MKMasashi Kamioka
Masashi Kamioka
NHNaoko Hijioka
Naoko Hijioka
SYShinya Yamada
Shinya Yamada
TYTetsuro Yokokawa
Tetsuro Yokokawa
YTYasuchika Takeishi
Yasuchika Takeishi
Background: The mechanism of esophageal thermal injury (ETI; esophageal mucosal injury and periesophageal nerve injury leading to gastric hypomotility) remains unknown when using a high-power short-duration (HP-SD) setting. This study sought to evaluate the characteristics of esophageal injuries in atrial fibrillation ablation using a HP-SD setting. Methods: After exclusion of 5 patients with their esophagus at the right portion of left atrium and 21 patients with additional ablations such as box isolation and low voltage area ablation in left atrium posterior wall, 271 consecutive patients (62±10 years, 56 women) who underwent pulmonary vein isolation by radiofrequency catheter ablation were analyzed. In the 101 patients, a HP-SD setting at 45 to 50 W with an Ablation Index module was used (HP-SD group). In the remaining 170 patients before introduction of the HP-SD setting, a conventional power setting of 20 to 30 W with contact force monitoring was used (conventional group). We performed esophagogastroduodenoscopy after pulmonary vein isolation in all patients and investigated the incidence and characteristics of ETI. Results: Although the incidence of ETI was significantly higher in the HP-SD group compared with the conventional group (37% versus 22%, P =0.011), the prevalence of esophageal lesions did not differ between the groups (7% versus 8%). Multivariate logistic regression analysis revealed that the use of the HP-SD setting (odds ratio, 6.09, P <0.001), and the parameters that suggest anatomic proximity surrounding the esophagus, were independent predictors of ETI. However, the majority of ETI in the HP-SD group was gastric hypomotility, and the thermal injury was limited to the shallow layer of the periesophageal wall using the HP-SD setting. Conclusions: Although the use of the HP-SD setting was a strong predictor of ETI, it could avoid deeper thermal injuries that reach the esophageal mucosal layer.

1 March 2021 in JACC: Cardiooncology
Verified
Journal Article
Open access
TYTetsuro Yokokawa
Tetsuro Yokokawa
TMTomofumi Misaka
Tomofumi Misaka
YKYusuke Kimishima
Yusuke Kimishima
KWKento Wada
Kento Wada
KMKeiji Minakawa
Keiji Minakawa
YTYasuchika Takeishi
Yasuchika Takeishi

2 November 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KWKento Wada
Kento Wada
TMTomofumi Misaka
Tomofumi Misaka
TYTetsuro Yokokawa
Tetsuro Yokokawa
YKYusuke Kimishima
Yusuke Kimishima
TKTakashi Kaneshiro
Takashi Kaneshiro
YTYasuchika Takeishi
Yasuchika Takeishi
Background: Blood‐based DNA methylation patterns are linked to types of diseases. FKBP prolyl isomerase 5 (FKBP5), a protein cochaperone, is known to be associated with the inflammatory response, but the regulatory mechanisms by leukocyte FKBP5 DNA methylation in patients with dilated cardiomyopathy (DCM) remain unclear. Methods and Results: The present study enrolled patients with DCM (n=31) and age‐matched and sex‐matched control participants (n=43). We assessed FKBP5 CpG (cytosine‐phosphate‐guanine) methylation of CpG islands at the 5′ side as well as putative promoter regions by methylation‐specific quantitative polymerase chain reaction using leukocyte DNA isolated from the peripheral blood. FKBP5 CpG methylation levels at the CpG island of the gene body and the promoter regions were significantly decreased in patients with DCM. Leukocyte FKBP5 and IL‐1β (interleukin 1β) mRNA expression levels were significantly higher in patients with DCM than in controls. The protein expressions of DNMT1 (DNA methyltransferase 1) and DNMT3A (DNA methyltransferase 3A) in leukocytes were significantly reduced in patients with DCM. In vitro methylation assay revealed that FKBP5 promoter activity was inhibited at the methylated conditions in response to immune stimulation, suggesting that the decreased FKBP5 CpG methylation was functionally associated with elevation of FKBP5 mRNA expressions. Histological analysis using a mouse model with pressure overload showed that FKBP5‐expressing cells were substantially infiltrated in the myocardial interstitium in the failing hearts, indicating a possible role of FKBP5 expressions of immune cells in the cardiac remodeling. Conclusions: Our findings demonstrate a link between specific CpG hypomethylation of leukocyte FKBP5 and DCM. Blood‐based epigenetic modification in FKBP5 may be a novel molecular mechanism that contributes to the pathogenesis of DCM.

21 December 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
NHNaoko Hijioka
Naoko Hijioka
MKMasashi Kamioka
Masashi Kamioka
YMYoshiyuki Matsumoto
Yoshiyuki Matsumoto
MNMinoru Nodera
Minoru Nodera
SYShinya Yamada
Shinya Yamada
YTYasuchika Takeishi
Yasuchika Takeishi

2 April 2019 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TYTetsuro Yokokawa
Tetsuro Yokokawa
HKHiroyuki Kunii
Hiroyuki Kunii
TKTakashi Kaneshiro
Takashi Kaneshiro
SIShohei Ichimura
Shohei Ichimura
AYAKIOMI YOSHIHISA
AKIOMI YOSHIHISA
YTYasuchika Takeishi
Yasuchika Takeishi
Takayasu arteritis is a rare systemic vasculitis, which affects the aorta and its major branches, especially in young females. Diagnosis and treatment for Takayasu arteritis with coronary stenosis are important to prevent fatal complications. Immunosuppressive treatment such as corticosteroid is a common treatment for this condition. However, the effects of immunosuppressive treatment on inflammatory coronary stenosis caused by Takayasu arteritis remains unknown. An 18-year-old female had chest oppression on effort and was referred to our hospital due to ST-segment depression in I, aVL, and V2–4 on electrocardiogram. Coronary angiography showed severe stenosis in the ostium of both the left main trunk and the right coronary artery. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography showed isolated inflammation of the aortic root. She was diagnosed with Takayasu arteritis and treated with combined immunosuppressive treatment with corticosteroid and tocilizumab, which decreased the FDG uptake in the aortic root. Four months after initiation of the immunosuppressive treatment, coronary angiography showed regression of the coronary ostial stenosis. Coronary artery bypass surgery was considered, but the patient rejected invasive revascularization for coronary artery disease. She did not have chest oppression or ST-segment depression after the immunosuppressive treatment. She had no cardiac events for 6 months after discharge. We described regressed coronary ostial stenosis in a young female patient with Takayasu arteritis. Immunosuppressive treatment might have a favorable effect on coronary ostial stenosis in Takayasu arteritis.

18 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SYShinya Yamada
Shinya Yamada
TKTakashi Kaneshiro
Takashi Kaneshiro
AYAKIOMI YOSHIHISA
AKIOMI YOSHIHISA
MNMinoru Nodera
Minoru Nodera
KAKazuaki Amami
Kazuaki Amami
YTYasuchika Takeishi
Yasuchika Takeishi
Background: Liver function may be a useful indicator of response to cardiac resynchronization therapy (CRT). We aimed to investigate the clinical significance of albumin-bilirubin (ALBI) score, an assessment tool of liver function, on outcomes in heart failure (HF) patients treated with CRT. Methods: We studied 180 patients undergoing CRT. The ALBI score, derived from albumin and total bilirubin, and left ventricular ejection fraction (LVEF) were assessed before and 6 months after CRT. The patients were classified according to the ALBI score before CRT; High (>−2.60) or Low (≤−2.60) ALBI groups. The patients were then reclassified based on the ALBI score before and 6 months after CRT; High/High, High/Low, Low/High, and Low/Low ALBI groups. We evaluated the prognostic value of the ALBI score for HF deaths after CRT. Results: During a median follow-up period of 50 months, there were 41 (22.7%) HF deaths. A Cox proportional hazard analysis revealed that high ALBI scores at baseline were not related to HF deaths (hazard ratio, 1.907, p = 0.068). However, High/High ALBI scores, but not High/Low or Low/High ALBI scores, were an independent predictor of HF deaths compared with Low/Low ALBI scores (hazard ratio, 3.449, p = 0.008), implying that consistently high ALBI scores were associated with poor prognosis. The percentage change in LVEF from baseline to 6 months after CRT did not differ among the four groups, suggesting that left ventricular systolic function was not linked with the ALBI score. Conclusions: ALBI scores before and after CRT are a new indicator of CRT response, and have a predictive value for HF deaths in HF patients.